Quantitative Diagnosis of Early-Stage Liver Cirrhosis* with Contrast-Enhanced Ultrasound A Clinical Study



Similar documents
Contrast-Enhanced Ultrasound (CEUS)

Surveillance for Hepatocellular Carcinoma

Geir Folvik, MD Division of Gastroenterology Department of Medicine, Haukeland University Hospital Bergen, Norway

Overview of the Cardiovascular System

Impact of Model-based Risk Analysis for Liver Surgery Planning

Non-invasive evaluation of liver fibrosis: current clinical use and next perspectives (chronic hepatitis C)

The State of the Liver in the Adult Patient after Fontan Palliation

Applications of Doppler Ultrasound in Fetal Growth Assessment. David Cole

The most relevant new technlogies ULTRASOUND

Recanalized Umbilical Vein in the Presence of Cirrhosis-Induced Portal Hypertension

Ischemia and Infarction

Role of Body Weight Reduction in Obesity-Associated Co-Morbidities

School of Diagnostic Medical Sonography Course Catalog

A912: Kidney, Renal cell carcinoma

Liver Function Essay

Ventilation Perfusion Relationships

Upper Extremity Vein Mapping for Placement of a Dialysis Access

KIDNEY FUNCTION RELATION TO SIZE OF THE TUMOR IN RENAL CELL CANCINOMA

Preparation iagnostic Medical Sonographer Overview"

School of Diagnostic Medical Sonography Course Catalog

Hepatitis C Treatment Criteria Commercial & Minnesota Health Care Programs

LIVER TUMORS PROFF. S.FLORET

Subclavian Steal Syndrome By Marta Thorup

Cardiac Masses and Tumors

EFSUMB EUROPEAN FEDERATION OF SOCIETIES FOR ULTRASOUND IN MEDICINE AND BIOLOGY Building a European Ultrasound Community

SAMSUNG ULTRASOUND RS80A

Clinical Practice Guidelines for Hepatocellular Carcinoma, List of Clinical Questions/Recommendations. Chapter. Grade. CQ No. 1 Interferon Therapy

Hepatocellular Carcinoma: A Guide to Screening and Diagnosis

VFI Technology to Change the Way You Work

Study of Effects of Probiotic Lactobacilli in Preventing Major Complications in Patients of Liver Cirrhosis

Biol 111 Comparative & Human Anatomy Lab 9: Circulatory System of the Cat Spring 2014

LIVER CANCER AND TUMOURS

OBJECTIVES By the end of this segment, the community participant will be able to:

Abdominal CT Perfusion: Effects of Breath Control Technique

Service Definition with all Clinical Terms Service: Laprascopic Cholecystectomy Clinic (No Gallstones in bile duct)

Summary of the risk management plan (RMP) for Ofev (nintedanib)

Ultrasound Simulators

Benign Liver Tumors. Cameron Schlegel PGY-1 3/6/2013

Functions of Blood System. Blood Cells

High-quality/High-resolution Digital Ultrasound Diagnostic Scanner

Sonographic Demonstration of Couinaud s Liver Segments

Introduction Breast cancer is cancer that starts in the cells of the breast. Breast cancer happens mainly in women. But men can get it too.

Your Guide to Express Critical Illness Insurance Definitions

Duplication Images in Vascular Sonography

Milwaukee School of Engineering Case Study: Factors that Affect Blood Pressure Instructor Version

OHTAC Recommendation

TCD in Intensive Care

Doppler. Doppler. Doppler shift. Doppler Frequency. Doppler shift. Doppler shift. Chapter 19

X-Plain Subclavian Inserted Central Catheter (SICC Line) Reference Summary

Ultrasound in Vascular Surgery. Torbjørn Dahl

MRI of Bone Marrow Radiologic-Pathologic Correlation

Specific Basic Standards for Osteopathic Fellowship Training in Cardiology

Distance Learning Program Anatomy of the Human Heart/Pig Heart Dissection Middle School/ High School

Surgery Support System as a Surgeon s Advanced Hand and Eye

PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES

GE Healthcare. Vivid 7 Dimension Cardiovascular Ultrasound System

Renovascular Hypertension

Low-gradient severe aortic stenosis with normal LVEF: A disturbing clinical entity

Acute on Chronic Liver Failure: Current Concepts. Disclosures

Atrial fibrillation: medicines to help reduce your risk of a stroke what are the options?

HEPATOCELLULAR CARCINOMA (HCC) RESECTION VERSUS TRANSPLANTATION. Francis Yao, M.D.

Principles of Medical Ultrasound. Pai-Chi Li Department of Electrical Engineering National Taiwan University

RayBio Creatine Kinase (CK) Activity Colorimetric Assay Kit

Heart and Vascular System Practice Questions

Ultrasound - Vascular

Metastatic Renal Cell Carcinoma: Staging and Prognosis of Three Separate Cases.

Cystic Lung Diseases. Melissa Price Gillian Lieberman, MD Advanced Radiology Clerkship Beth Israel Deaconess Medical Center November, 2008

A t h e n s I n s t i t u t e o f U l t r a s o u n d S u n s e t D r i v e A t h e n s G A

Chapter 19 Ci C r i cula l t a i t o i n

EVALUATION OF LIVER FIBROSIS BY FIBROSCAN

it s all Choices about S H R P School of Health Related Professions Vascular Technology

BACKGROUND MEDIA INFORMATION Fast facts about liver disease

Republic Polytechnic. Continuing Education & Training. Course Structure: Anatomy & Physiology

Anaerobic and Aerobic Training Adaptations. Chapters 5 & 6

Non-alcoholic fatty liver disease: Prognosis and Treatment

Alpha-fetoprotein

Case III. Disscussion. the UHP ultrasound protocol. Novel Ultrasound Approach to the Empiric Evaluation of the Undifferentiated Hypotensive Patient

Transmission of HCV in the United States (CDC estimate)

Kidney Cancer OVERVIEW

Leading the New Standards

Pathophysiology of Portal Hypertension

Characterization of small renal lesions: Problem solving with MRI Gary Israel, MD

Ny teknologi: Fagdagene ved St. Olavs Hospital Lasse Løvstakken Dept. Circulation and Medical Imaging

CARDIAC SONOGRAPHER SERIES

Ultrasound Tissue Characterization an innovative method to visualize and monitor Patellar Tendinopathy

Edwards FloTrac Sensor & Edwards Vigileo Monitor. Understanding Stroke Volume Variation and Its Clinical Application

n/a MYSTERY OF THE BLOOD STAIN (RE)

Company profile. Quote from the analyst of. Company Milestone. Feel the Difference. Tel: Fax:

Dr. Linde is an international beauty expert and an acclaimed keynote speaker at conferences all over the world. He is specialized in the treatment of

AI CPT Codes. x x MRI Magnetic resonance (eg, proton) imaging, temporomandibular joint(s)

An abdominal ultrasound produces a picture of the organs and other structures in the upper abdomen.

What to Expect from Intestinal Ultrasonography

Come valutare la risposta o la progressione nei pazienti in trattamento con terapie biologiche

Biology 224 Human Anatomy and Physiology II Week 8; Lecture 1; Monday Dr. Stuart S. Sumida. Excretory Physiology

Alcohol and the Liver

Comparative Levels of ALT, AST, ALP and GGT in Liver associated Diseases

Liver Transplantation for Hepatocellular Carcinoma. John P. Roberts, MD Chief, Division of Transplant Service University of California, San Francisco

Optic Disc Drusen. Normal Enlarged view of Optic Disc. Lumpy Appearance of Optic Disc. Optic Disc Drusen With Drusen

NP/PA Clinical Hepatology Fellowship Summary of Year-Long Curriculum

The TV Series. INFORMATION TELEVISION NETWORK

Transcription:

original papers dv Clin Exp Med 2012, 21, 3, 385 390 ISSN 1899 5276 Copyright by Wroclaw Medical University Ying Shi, Xing-Hua Wang, Guo-Chang Xia, Cheng-Gong Lei Quantitative Diagnosis of Early-Stage Liver Cirrhosis* with Contrast-Enhanced Ultrasound Clinical Study Ilościowe rozpoznanie wczesnego stadium marskości wątroby za pomocą USG z kontrastem badanie kliniczne Department of Ultrasound, the 2 nd Hospital of Shanxi Medical University, Taiyuan, China bstract Objectives. To investigate the quantitative diagnosis value of contrast-enhanced ultrasound (CEUS) for early-stage liver cirrhosis. Material and Methods. total of 15 healthy subjects and 15 patients with cirrhosis were recruited into the present study, and the hepatic artery, portal vein, hepatic vein and liver parenchyma were dynamically monitored under ultrasonography and then qualified with the QL time-intensity curve to obtain the arriving time (T) and the peak time (PT) of the hepatic artery, portal vein, hepatic vein and liver parenchyma. The hepatic artery to hepatic vein transit time (H-HVTT = HVT-HT) and portal vein to hepatic vein transit time (PV-HVTT = HVT- PVT) were calculated. Results. The T of the hepatic vein was significantly shorter than that in controls (P < 0.01); the H-HVTT and PV-HVTT in cirrhosis patients were also significantly shorter than those in controls (P < 0.01). However, the PT in patients was significantly prolonged when compared with controls (P < 0.05). Conclusions. The T of the hepatic vein, the transit time of the liver and the PT of liver parenchyma can be used as non-invasive indicators in the quantitative diagnosis of early-stage liver cirrhosis (dv Clin Exp Med 2012, 21, 3, 385 390). Key words: ultrasonography, contrast agent, liver cirrhosis. Streszczenie Cel pracy. Zbadanie ilościowe rozpoznania wczesnego stadium marskości wątroby za pomocą USG wzmocnionego kontrastem (CEUS). Materiał i metody. Do badań włączono 15 osób zdrowych i 15 chorych na marskość wątroby. Tętnica wątrobowa, żyła wrotna, żyła wątrobowa i miąższ wątroby były dynamicznie monitorowane za pomocą USG. Na podstawie krzywej zależności intensywności od czasu QL uzyskano czas przybycia (T) i czas szczytu (PT) tętnicy wątrobowej, żyły wrotnej, żyły wątrobowej i miąższu wątroby. Obliczono czas przejścia tętnicy wątrobowej do żyły wątrobowej (H-HVTT = HVT- HT) oraz czas przejścia żyły wrotnej do żyły wątrobowej (PV-HVTT = HVT-PVT). Wyniki. T żyły wątrobowej był znacznie krótszy niż w grupie kontrolnej (p < 0,01); H-HVTT i PV-HVTT u pacjentów z marskością były też znacznie krótsze niż w grupie kontrolnej (p < 0,01). PT u chorych był znacznie dłuższy w porównaniu z grupą kontrolną (p < 0,05). Wnioski. T żyły wątrobowej, czas przejścia przez wątrobę i PT miąższu wątroby mogą być używane jako nieinwazyjne wskaźniki ilościowe rozpoznania wczesnego stadium marskości wątroby (dv Clin Exp Med 2012, 21, 3, 385 390). Słowa kluczowe: ultrasonografia, środek kontrastowy, marskość wątroby. * This research was supported by 2010 Science and Technology Project of Shanxi Province (No. 20100311096-2).

386 Y. Shi et al. Liver fibrosis is a reversible process in the early development of chronic liver diseases. Therefore, early diagnosis and dynamic monitoring of liver fibrosis may significantly improve the prognosis of chronic liver diseases. No pronounced morphological changes are noted in the early stage of liver cirrhosis, which renders a great challenge in the early imaging diagnosis of liver cirrhosis. It has been shown that there are alterations in the hemodynamics in early-stage liver cirrhosis [1]. Conventional ultrasonography cannot identify the changes in hemodynamics which significantly compromises the sensitivity and specificity of ultrasound in the diagnosis of early-stage liver cirrhosis. With the development of contrast-enhanced ultrasound (CEUS) technology, an ultrasound contrast reagent has been applied in the evaluation of perfusion in organs which may mirror the changes in microcirculation and hemodynamics in early-stage liver cirrhosis to achieve accurate early diagnosis of early-stage liver cirrhosis. In the present study, a series of dynamic parameters of the hepatic artery, hepatic vein, portal vein and liver parenchyma were determined under CEUS to evaluate the microcirculation in early-stage liver cirrhosis and explore the role of these parameters in the diagnosis of early-stage liver cirrhosis. Material and Methods Patients and Grouping total of 15 healthy subjects (8 males and 7 females) with a mean age of 44.9 years (range: 28~48 years) were selected in the control group. total of 15 patients with suspected liver cirrhosis (11 males and 4 females) with a mean age of 55.4 years (range: 31~62 years) were recruited from the Department of Gastroenterology from November 2008 to July 2009 as the liver cirrhosis group. mong them, there was 1 patient with drug-induced liver cirrhosis, 2 patients with alcoholic cirrhosis, 11 patients with posthepatitis cirrhosis and 1 patient with posthepatitis C cirrhosis. Liver cirrhosis was pathologically proved to be at the early stage. Ultrasound Equipment and Contrast gent The Philips IU22 Ultrasonic Diagnostic pparatus with a diagnostic probe frequency of 3.5~5.0 MHz and mechanical index (MI) of 0.8 was used in this study. The ultrasound contrast reagent (SonoVue; racco, Italy) contains the active substance sulphur hexafluoride (SF6) wrapped by phospholipids. efore use, the SonoVue was dissolved in 5 ml of normal saline followed by vortex mixing. Then, 2.4 ml of SonoVue solution (5 mg/ml) was rapidly infused through the cubital vein followed by rapid infusion of 5 ml of normal saline. The VCD and internal station were used to detect immediately after infusion. If necessary, a second infusion was carried out 15 min later. Ultrasonography Conventional two-dimensional ultrasound was used to scan the liver. The morphology of the liver and its capsule, echo of liver parenchyma as well as the intrahepatic vessels were detected. Then, color Doppler ultrasound was used to detect the flow rate of the hepatic artery, portal vein and hepatic vein followed by achieving a preliminary diagnosis. The location of the probe was adjusted to obtained a favorable image of the right liver lobe in which the hepatic artery, portal vein and hepatic vein can be identified. Then, the mode was switched to CEUS followed by infusion of the contrast. The hepatic artery, portal vein, hepatic vein and liver parenchyma were dynamically monitored, and all images were stored for use. Data cquisition The data was analyzed by 2 ultrasound practitioners independently. The changes were dynamically analyzed with the software (QL-intensity curve). The arriving time (T) and peaking time (PT) of the hepatic artery, portal vein, hepatic vein and liver parenchyma were determined. The hepatic artery to hepatic vein transit time (H- HVTT = HVT-HT) and the portal vein to hepatic vein transit time (PV-HVTT = HVT- PVT) were calculated. Statistical nalysis Statistical analysis was carried out with SPSS 11.0 statistical software and qualitative data was presented as and analyzed with a paired t test. value of P < 0.05 was considered statistically significant. Results There were no significant differences in the Ts of the hepatic artery and portal vein (Figure 1

Quantitative Ultrasound Diagnosis of Early-Stage Liver Cirrhosis 387 Fig. 1. ) Visualization of the hepatic artery after infusion of ultrasound contrast in healthy controls; ) visualization of the hepatic artery after infusion of ultrasound contrast in cirrhosis patients Ryc. 1. ) Wizualizacja tętnicy wątrobowej po podaniu kontrastu ultrasonograficznego w grupie kontrolnej, ) wizualizacja tętnicy wątrobowej po podaniu kontrastu ultrasonograficznego u chorych na marskość Fig. 2. ) Visualization of the portal vein after infusion of ultrasound contrast in controls; ) visualization of the portal vein after infusion of ultrasound contrast in cirrhosis patients Ryc. 2. ) Wizualizacja żyły wrotnej po podaniu kontrastu ultrasonograficznego w grupie kontrolnej, ) wizualizacja żyły wrotnej po podaniu kontrastu ultrasonograficznego u chorych na marskość Fig. 3. ) Visualization of the hepatic vein after infusion of ultrasound contrast in controls; ) visualization of the hepatic vein after infusion of ultrasound contrast in cirrhosis patients Ryc. 3. ) Wizualizacja żyły wątrobowej po podaniu kontrastu ultrasonograficznego w grupie kontrolnej, ) wizualizacja żyły wątrobowej po podaniu kontrastu ultrasonograficznego u chorych na marskość and Figure 2). In the cirrhosis patients, the T of the hepatic vein was significantly shorter than that in the controls (P < 0.01) (Table 1 and Figure 3). The H-HVTT and PV-HVTT in cirrhosis patients were markedly shorter than those in controls (P < 0.01) (Table 2 and Figure 4). However, there were no significant differences in the PTs of the hepatic artery, portal vein and hepatic vein between the two groups. Moreover, the PT of the liver parenchyma was markedly prolonged in cirrhosis patients when compared with controls (P < 0.05) (Table 3).

388 Y. Shi et al. Table 1. Ts in cirrhosis patients and healthy controls (x ± s) Tabela 1. T u chorych na marskość wątroby i w grupie kontrolnej Hepatic artery(s) (HT) (Tętnica wątrobowa) Portal vein(s) (PVT) (Żyła wrotna) Hepatic vein(s) (Żyła wątrobowa) Note: *P < 0.01 vs controls. Control group (n=) (Grupa kontrolna) Patient group (n=) (Grupa badana) 14.66 ± 1.90 14.84 ± 4.00 0.145 0.881 18.59 ± 3.45 20.49 ± 5.71 0.989 0.336 29.00 ± 3.81 21.58 ± 4.18* 4.544 0.000 *P < 0,01 vs grupy kontrolnej. t P Fig. 4. ) Time-intensity curve after infusion of ultrasound contrast in controls; ) Time-intensity curve after infusion of ultrasound contrast in cirrhosis patients (yellow: hepatic artery; red: portal vein; green: hepatic vein) Ryc. 4. ) Krzywa zależności intensywności od czasu po podaniu kontrastu ultrasonograficznego w grupie kontrolnej, ) krzywa zależności intensywności od czasu po podaniu kontrastu ultrasonograficznego u chorych na marskość (żółty: tętnica wątrobowa; czerwony: żyła wrotna; zielony: żyła wątrobowa) Table 2. Transit time in cirrhosis patients and healthy controls (x ± s) Tabela 2. Czas przejścia u chorych na marskość wątroby i w grupie kontrolnej Control group (n=) (Grupa kontrolna) Patient group (n=) (Grupa badana) H-HVTT 14.34 ± 2.66 6.74 ± 2.34* 7.431 0.000 PV-HVTT 10.41 ± 3.49 5.65 ± 3.31* 3.427 0.002 Note: *P < 0.01 vs. controls. *P < 0,01 vs grupy kontrolnej. t P Table 3. PTs in cirrhosis patients and healthy controls (x ± s) Tabela 3. PT u chorych na marskość wątroby i w grupie kontrolnej Hepatic artery(s) (HPT) (Tętnica wątrobowa) Portal vein(s) (PVPT) (Żyła wrotna) Hepatic vein(s) (HVPT) (Żyła wątrobowa) Liver parenchyma (Miąższ wątroby) Note: P < 0.05 vs. controls. Control group (n=) (Grupa kontrolna) Patient group (n=) (Grupa badana) 26.75 ± 7.80 28.19 ± 7.92 0.346 0.732 35.35 ± 6.80 35.02 ± 10.70 0.153 0.879 45.71 ± 7.71 43.02 ± 11.10 0.576 0.056 34.01 ± 7.57 45.55 ± 7.6D 2.508 0.023 *P < 0,05 vs grupy kontrolnej. t P

Quantitative Ultrasound Diagnosis of Early-Stage Liver Cirrhosis 389 Discussion When diffuse lesions occur in the liver, the clinical manifestations are difficult to identify due to the potent compensation of liver function. Traditionally, ultrasound practitioners diagnose liver fibrosis according to changes in two-dimensional images and hemodynamics. However, two-dimensional ultrasound cannot be used to quantitate liver fibrosis and hemodynamics is frequently affected by several factors [2 4]. Therefore, the sensitivity and specificity of two-dimensional ultrasound are poor in the diagnosis of early-stage liver cirrhosis. Liver biopsy is the gold standard in the diagnosis of liver fibrosis and cirrhosis. However, liver biopsy is invasive and has poor repeatability limiting its wide application. With the development of CEUS technology, numerous clinical studies have shown application of ultrasound contrast can reflect the perfusion. Therefore, researchers have applied CEUS in the evaluation of microcirculation in early-stage liver cirrhosis, which may be beneficial for the early diagnosis of liver cirrhosis [5]. lbercht et al. [6] applied the transit time of ultrasound contrast reagent in the diagnosis of liver cirrhosis. In their study, the time to the signal of contrast in the hepatic vein of less than 24 seconds had a sensitivity of 100% and specificity of 96% in the diagnosis of liver cirrhosis. In the present study, the Ts of the hepatic vein in controls and patients were 29 seconds and 21 seconds, respectively. The analysis showed the T of the hepatic vein in cirrhosis patients was significantly shorter than that in controls, which was consistent with the study mentioned above. Hirota et al. [7] divided 40 patients into a noncirrhosis group and a compensated cirrhosis group. fter intravenous infusion of ultrasound contrast, the time to the signal of contrast in the hepatic artery, portal vein and hepatic vein was determined and the transit time of the liver was calculated. Their results showed the transit time in compensated cirrhosis patients was significantly shorter than that in non-cirrhosis patients. Present results revealed the H-HVTT and PV-HVTT were 6.7 seconds and 5.6 seconds, respectively, in cirrhosis patients and 14.3 seconds and 10.4 seconds, respectively, in controls. nalysis showed the H-HVTT and PV-HVTT in cirrhosis patients were markedly shortened when compared with controls, consistent with the study of Hirota et al. These findings imply the pathological alterations in liver fibrosis and cirrhosis result in changes in hemodynamics. The reasons may be as follows: t the early stage of liver cirrhosis, the intrahepatic hemodynamics is altered. The liver sinusoids are capillarized resulting in a shunt between the portal vein and hepatic vein (blood in the portal vein enters the hepatic vein). In addition, liver fibrosis may cause reconstruction of hepatic lobules resulting in neovascularization and formation of communicating branches between arteries and veins as well as subsequent arteriovenous shunt [8]. Under normal conditions, the ultrasound contrast enters the portal vein. Through the branches of the portal vein, the ultrasound contrast enters the liver sinusoids and subsequently the inferior vena cava via the hepatic vein. Due to alterations in hemodynamics at the early stage of liver cirrhosis, on one hand, the ultrasound contrast from the portal vein enters the hepatic vein via capillarized liver sinusoids bypassing the normal liver sinusoids. On the other hand, the ultrasound contrast from arteries enters the hepatic vein via the communicating branches between arteries and veins. These changes finally result in a significant shortening in the transit time of the liver and the T of the hepatic vein. In patients with liver fibrosis or cirrhosis, hyperdynamic circulation in all tissues is also a critical reason resulting in the shortened transit time of the liver. Portal hypertension in liver cirrhosis is characterized by the disorder of blood circulation in not only the liver and portal system, but the systemic blood vessels. In the disorder of circulation in systemic blood vessels, dilatation of peripheral arteries may cause hyperdynamic circulation characterized by increased cardiac output, elevated blood flow, increased heart rate and decrease of blood pressure and systemic vascular resistance. The enhancement in the liver parenchyma may be attributed to the phagocytosis of the ultrasound contrast by the Kupffer cells, resulting in a retention of ultrasound contrast in the sinusoid space or vessel walls, which may present a hyperecho under ultrasonography. In the present study, the PT of the liver parenchyma in cirrhosis patients was significantly prolonged when compared with controls, which was consistent with the results of Sugimoto [9]. They proposed there was hyperplasia and cell hypertrophy in cirrhosis, resulting in an increase in intrahepatic vascular resistance. Moreover, the fiber separation may cause changes in the anatomy of the liver. t this time, there is hyperplasia of fibrous connective tissues and collagen deposition in the perisinusoidal space involving capillary-like channels of hepatic sinusoids. These changes lead to reduction of vessel volume, which further increases portal pressure and decreases the blood supply to the portal vein [10 11]. Thus, the blood flow in hepatic sinusoids is slowed and the time of ultrasound contrast in the liver is prolonged, resulting in prolongation of the PT of the liver parenchyma.

390 Y. Shi et al. Taken together, CEUS can be performed to detect the T, transit time of the liver and the PT of liver parenchyma. These parameters can be used as indicators in the diagnosis of early-stage liver cirrhosis. However, the sensitivity and specificity of this method should be further investigated due to small sample size in the present study. References [1] Orrego H, lendis LM, Crossley IR, Medline, Macdonald, Ritchie S, Israel Y: Correlation of intrahepatic pressure with collagen in the Disuse space and hepatomegaly in humans and in the rat. Gastroenterology 1981, 80 (3), 546 556. [2] Zoli M, Magalotti D, ianchi G, Ghigi G, Orlandini C, Grimaldi M, Marchesini G, Pisi E: Functional hepatic flow and Doppler assessed total hepatic flow in control subjects and in patients with cirrhosis. J Hepatol 1995, 23(2), 129 134. [3] Sanford NL, Walsh P, Matis C, addeley H, Powell LW: Is ultrasonography useful in the assessment of diffuse parenchyma liver disease. Gastroenterology 1985, 89(1), 186 191. [4] Vilgrain V: Ultrasound of diffuse liver disease and portal hypertension. Eur Radiol 2001, 11(9), 1563 1577. [5] Strobel D, Krodel U, Martus P, Hahn EG, ecker D: Clinical evaluation of contrast-enhanced color Doppler sonography in the differential diagnosis of liver tumors. J Clin Ultrasound 2000, 28, 1 13. [6] lbrecht T, lomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley R, Urbank, utler- arnes J, Patel N: Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999, 353 (9164), 1579 1583. [7] Hirota M, Kaneko T, Sugimoto H, Kure S, Inoue S, Takeda S, Nakao : Intrahepatic circulatory time analysis of an ultrasound agent in liver cirrhosis. Liver Int 2005, 25 (2), 337. [8] Ohnishi K, Chin N, Sugita S, Saito M, Tanaka H, Terabayashi H, Saito M, Iida S, Nomura F, Okuda K: Quantitative aspects of portal systemic and arteiovenous shunts within the liver in cirrhosis. Gastroenterology 1987, 93 (1), 129 134. [9] Sugimoto H, Kaneko T, Hirota M, Tezel E, Nakao : Earlier hepatic vein transit-time measured by contrast ultrasonography reflects intra hepatic hemodynamic changes accompanying cirrhosis. J Hepatol 2002, 37 (5), 578 583. [10] Leen E, Goldberg J, nderson JR, Robertson J, Moule, Cooke TG, Mcrdle CS: Hepatic perfusion changes in patients with liver metastases comparison with those patients with cirrhosis. Gut 1993, 34 (4), 554 557. [11] Kleber G, Steudel N, ehrmann C, Zipprich, Hübner G, Lotterer E, Fleig WE: Hepatic arterial flow volume and reserve in patients with cirrhosis use of intra-arterial Doppler and adenosine infusion. Gastroenterology 1999, 116 (4), 906 914. ddress for correspondence: Xing-Hua Wang Department of Ultrasound the 2 nd Hospital of Shanxi Medical University Taiyuan, 030001 China Phone number: +86-(0)351-3524120 E-mail: docjack99@gmail.com Conflict of interest: None declared Received: 17.11.2011 Revised: 6.02.2012 ccepted: 6.06.2012